Launch of the VIOLET Study at University of Southampton
The University of Southampton, in collaboration with University Hospital Southampton (UHS), has launched the innovative VIOLET study, exploring the potential of a specialist diagnostic tampon to revolutionize early ovarian cancer detection. Led by Dr. Jemma Longley, a consultant medical oncologist at UHS, this trial marks a significant step forward in addressing one of the most challenging cancers to diagnose early. Ovarian cancer affects approximately 7,600 women annually in the UK, yet only 27% of cases are caught at the earliest stages, where survival rates exceed 95%.
Dr. Longley and her team from the Southampton Clinical Trials Unit (SCTU) and the Centre for Cancer Immunology aim to identify microRNA biomarkers—tiny biological signals—in vaginal fluid that could signal the presence of ovarian cancer cells before symptoms become severe. This non-invasive approach could empower high-risk women, such as those with BRCA gene mutations, to monitor their health without resorting immediately to preventive surgery, which often induces early menopause and long-term health complications.
The trial's timing aligns with the UK's Women's Health Strategy, emphasizing gender-specific healthcare improvements. As Dr. Victoria Goss, Head of Early Diagnosis and Translational Research at SCTU, notes, "This is an exciting trial in an area where better diagnosis is desperately needed."
The Silent Threat of Ovarian Cancer in the UK
Ovarian cancer remains the sixth most common cancer among women in the United Kingdom, claiming around 4,000 lives each year—that's 11 women daily. Symptoms like persistent bloating, feeling full quickly, frequent urination, and pelvic discomfort are often subtle and mistaken for gastrointestinal issues, delaying diagnosis until advanced stages. Cancer Research UK projects a modest rise in incidence rates by 5% between 2023-2025 and 2038-2040, underscoring the urgency for new screening tools.
Unlike breast or cervical cancer, no national screening program exists for ovarian cancer. High-risk groups, particularly carriers of BRCA1 or BRCA2 mutations, face lifetime risks up to 44% and 17%, respectively, compared to 1-2% in the general population. Preventive risk-reducing salpingo-oophorectomy (RRSO)—surgical removal of ovaries and fallopian tubes—is recommended from age 35-40 for BRCA1 carriers, but it triggers immediate menopause, increasing risks of osteoporosis, cardiovascular disease, and cognitive decline. The VIOLET study seeks to bridge this gap by offering a less invasive alternative.
🔬 How the Specialist Diagnostic Tampon Works
The core innovation of the VIOLET study is a medical-grade tampon provided by biotechnology firm Daye. Unlike standard tampons, this device is designed to collect vaginal fluid rich in potential biomarkers. Participants insert the tampon as they would during menstruation, allowing it to absorb fluids shed from the reproductive tract, including any microRNAs from early ovarian or fallopian tube cancers.
Step-by-step process:
- Insertion and Collection: Women undergoing RRSO at UHS use the tampon and vaginal swabs pre-surgery to gather fluid samples.
- Analysis: Samples are tested for microRNA changes—small non-coding RNAs dysregulated in cancer cells and detectable in proximal fluids.
- Comparison: Vaginal fluid data is cross-referenced with tissue from surgically removed ovaries and fallopian tubes, distinguishing cancerous from healthy profiles.
- Validation: Biomarker signatures are validated against known early-stage indicators.
This method builds on prior proofs-of-concept, such as a 2014 pilot detecting TP53 mutations in tampon samples from high-grade serous ovarian cancer patients with 60% sensitivity. If successful, it could evolve into an at-home screening kit, similar to HPV self-tests.
University of Southampton's Leadership in Cancer Research
The University of Southampton boasts a world-renowned Centre for Cancer Immunology, one of Europe's largest academic centers dedicated to immunotherapy and early detection. The SCTU, with over 100 trials annually, provides robust infrastructure for studies like VIOLET. Mr. David Constable-Phelps, consultant gynaecological oncology surgeon, emphasizes: "The ability to detect the earliest signs of ovarian cancer with a relatively non-invasive test such as the Daye tampon would be a complete game-changer."
Southampton's Experimental Cancer Medicine Centre supports translational research, accelerating lab discoveries to clinic. Recent funding of £2.5m for blood tests further highlights their commitment.Explore research positions at leading UK universities like Southampton. For those passionate about oncology, opportunities in clinical trials and immunology abound through platforms like University Jobs UK.
Photo by Sujay Paul on Unsplash
Trial Recruitment and Participant Experience
Currently recruiting at UHS, VIOLET targets women scheduled for RRSO due to elevated risk. Participants provide samples non-invasively, minimizing additional burden. Charlotte Stehr, a BRCA carrier under 40, shares: "I fear slipping through the cracks without screening—something comfortable like a tampon could change that." Early survivor Alison Farmer adds: "Far too many are diagnosed too late; this research is vital."
Benefits include contributing to science while gaining peace of mind; risks are minimal, akin to routine gyn exams. The trial's community focus could expand to population screening if biomarkers prove reliable.
Challenges in Ovarian Cancer Early Detection
Current diagnostics rely on CA125 blood tests (low specificity), transvaginal ultrasound, and symptom awareness—ineffective for pre-symptomatic high-risk cases. Biomarkers like microRNAs offer promise: stable, tissue-specific, and detectable in fluids. Previous tampon studies for endometrial cancer (DETECT trial) showed feasibility, detecting mutations in 38-60% of cases.
- False Positives/Negatives: Validation needed to balance sensitivity/specificity.
- Accessibility: At-home use reduces clinic visits, aiding underserved areas.
- Equity: Addresses postmenopausal focus; applicable to premenopausal high-risk.
Integration with NHS could mirror cervical screening success, saving lives and NHS costs (£500m+ annually on late-stage treatment).
Funding, Partnerships, and Broader Impact
The Eve Appeal funds VIOLET, recognizing its potential to transform gynaecological cancer care. Daye's tampon tech stems from HPV/endometriosis detection innovations. Southampton's partnerships exemplify UK higher ed's role in health innovation.Aspiring researchers can prepare impactful CVs for such trials.
Success could spawn spin-outs, jobs in biotech. BBC coverage highlights public excitement. CRUK stats underscore need.
Stakeholder Perspectives and Ethical Considerations
Patients advocate for accessible screening; oncologists like Dr. Longley stress avoiding overtreatment. Ethically, informed consent covers biomarker privacy; diverse recruitment ensures equity. Gynaecologists note fallopian tubes as primary origin (80% HGSC), validating vaginal proximity.
Mr. Constable-Phelps: "We are optimistic about biological signals in early tumours." Aligns with NIHR priorities.
Photo by Wyxina Tresse on Unsplash
Future Outlook: From Trial to Screening Revolution
If VIOLET identifies reliable microRNAs, a phase II/III community trial follows, potentially NHS-integrated by 2030. Projections: 14% mortality drop by 2040 could accelerate with screening. Global implications for low-resource settings.
For higher ed, boosts med student training in trials. Browse higher ed jobs in research; Rate professors in oncology; Career advice for academics.
This Southampton-led effort exemplifies UK universities' pivotal role in lifesaving innovation.
